https://rheumatologydigest.org/tags/jak-inhibitors/Recent content in Jak-Inhibitors on Rheumatology DigestHugoen-usWed, 20 May 2026 06:00:00 +0530https://rheumatologydigest.org/posts/brepocitinib-dermatomyositis-valor/Wed, 20 May 2026 06:00:00 +0530https://rheumatologydigest.org/posts/brepocitinib-dermatomyositis-valor/The VALOR phase 3 trial shows that brepocitinib 30 mg daily — a selective TYK2–JAK1 inhibitor — significantly improves composite disease activity, skin involvement, and muscle strength while enabling steroid discontinuation in adults with treatment-refractory dermatomyositis, marking the first successful phase 3 RCT of an oral targeted agent in this disease.